The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
CTLA-4 ligation blocks CD28-dependent T cell activation.
Open accessAbstract
CTLA-4 is a CD28 homologue believed to be a negative regulator of T cell function. However, the mechanism of this downregulatory activity is not well understood. The present study was designed to examine the effect of CTLA-4 ligation on cytokine production, cell survival, and cell cycle progression. The results demonstrate that the primary effect of CTLA-4 ligation is not the induction of apoptosis. Instead, CTLA-4 signaling blocks IL-2 production, IL-2 receptor expression, and cell cycle progression of activated T cells. Moreover, the effect of CTLA-4 signaling was manifested after initial T cell activation. Inhibition of IL-2 receptor expression and cell cycle progression was more pronounced at late (72 h) time points after initial activation. The effects of anti-CTLA-4 mAbs were most apparent in the presence of optimal CD28-mediated costimulation consistent with the finding that CTLA-4 upregulation was CD28-dependent. Finally, the addition of exogenous IL-2 to the cultures restored IL-2 receptor expression and T cell proliferation. These results suggest that CTLA-4 signaling does not regulate cell survival or responsiveness to IL-2, but does inhibit CD28-dependent IL-2 production.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Self-citationLymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis
Watanabe-Fukunaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A., & Nagata, S. (1992) · Nature · doi:10.1038/356314a0 · Cited by 2,885
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Self-citationCTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685
Identification of a monoclonal antibody specific for a murine T3 polypeptide.
Leo, O., Foo, M., Sachs, D. H., Samelson, L. E., & Bluestone, J. A. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.5.1374 · Cited by 1,593
Self-citationA new member of the immunoglobulin superfamily—CTLA-4
Brunet, J.-F., Denizot, F., Luciani, M.-F., Roux-Dosseto, M., Suzan, M., Mattei, M.-G., & Golstein, P. (1987) · Nature · doi:10.1038/328267a0 · Cited by 1,306
Unkeless, J. C. (1979) · The Journal of experimental medicine · doi:10.1084/jem.150.3.580 · Cited by 1,237
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL
Boise, L. H., Minn, A. J., Noel, P. J., June, C. H., Accavitti, M. A., Lindsten, T., & Thompson, C. B. (1995) · Immunity · doi:10.1016/1074-7613(95)90161-2 · Cited by 1,210
Cited by
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Read, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Sharpe, A. H., & Freeman, G. J. (2002) · Nature Reviews Immunology · doi:10.1038/nri727 · Cited by 1,712
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
The CD28 Signaling Pathway Regulates Glucose Metabolism
Frauwirth, K. A., Riley, J. L., Harris, M. H., Parry, R. V., Rathmell, J. C., Plas, D. R., Elstrom, R. L., June, C. H., & Thompson, C. B. (2002) · Immunity · doi:10.1016/s1074-7613(02)00323-0 · Cited by 1,475
ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
Hutloff, A., Dittrich, A. M., Beier, K. C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, I., & Kroczek, R. A. (1999) · Nature · doi:10.1038/16717 · Cited by 1,482
Penna, G., & Adorini, L. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.5.2405 · Cited by 1,267
Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways
Fife, B. T., & Bluestone, J. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00662.x · Cited by 1,054
Self-citationB7-H3: A costimulatory molecule for T cell activation and IFN-γ production
Chapoval, A. I., Ni, J., Lau, J. S., Wilcox, R. A., Flies, D. B., Liu, D., Dong, H., Sica, G. L., Zhu, G., Tamada, K., et al. (2001) · Nature Immunology · doi:10.1038/85339 · Cited by 1,015
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Complexities of CD28/B7: CTLA-4 Costimulatory Pathways in Autoimmunity and Transplantation
Salomon, B., & Bluestone, J. A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.225 · Cited by 1,006
Self-citationChambers, C. A., Kuhns, M. S., Egen, J. G., & Allison, J. P. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.565 · Cited by 998
CTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940
Huang, R., & Zhou, P.-K. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00648-7 · Cited by 907
Carreno, B. M., & Collins, M. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.091101.091806 · Cited by 896
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
Walker, L. S. K., & Sansom, D. M. (2011) · Nature Reviews Immunology · doi:10.1038/nri3108 · Cited by 786
Molecular Mechanisms of Treg-Mediated T Cell Suppression
Schmidt, A., Oberle, N., & Krammer, P. H. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00051 · Cited by 761
IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
Abiko, K., Matsumura, N., Hamanishi, J., Horikawa, N., Murakami, R., Yamaguchi, K., Yoshioka, Y., Baba, T., Konishi, I., & Mandai, M. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.101 · Cited by 725
Induction of Peripheral T Cell Tolerance In Vivo Requires CTLA-4 Engagement
Perez, V. L., Van Parijs, L., Biuckians, A., Zheng, X. X., Strom, T. B., & Abbas, A. K. (1997) · Immunity · doi:10.1016/s1074-7613(00)80284-8 · Cited by 716
The Emerging Role of CTLA-4 as an Immune Attenuator
Thompson, C. B., & Allison, J. P. (1997) · Immunity · doi:10.1016/s1074-7613(00)80366-0 · Cited by 634
Downey, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624
The enemy within: keeping self-reactive T cells at bay in the periphery
Walker, L. S. K., & Abbas, A. K. (2002) · Nature Reviews Immunology · doi:10.1038/nri701 · Cited by 596
The Role of T-Cell Costimulatory Activation Pathways in Transplant Rejection
Sayegh, M. H., & Turka, L. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806183382506 · Cited by 577
CD80 (B7-1) Binds Both CD28 and CTLA-4 with a Low Affinity and Very Fast Kinetics
van der Merwe, P. A., Bodian, D. L., Daenke, S., Linsley, P., & Davis, S. J. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.3.393 · Cited by 551
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Schildberg, F. A., Klein, S. R., Freeman, G. J., & Sharpe, A. H. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.002 · Cited by 542
Tumor Immunology and Tumor Evolution: Intertwined Histories
Galon, J., & Bruni, D. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.018 · Cited by 540
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L.-S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 532
Coordinate Regulation of Complex T Cell Populations Responding to Bacterial Infection
Busch, D. H., Pilip, I. M., Vijh, S., & Pamer, E. G. (1998) · Immunity · doi:10.1016/s1074-7613(00)80540-3 · Cited by 508
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Naimi, A., Mohammed, R. N., Raji, A., Chupradit, S., Yumashev, A. V., Suksatan, W., Shalaby, M. N., Thangavelu, L., Kamrava, S., Shomali, N., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00854-y · Cited by 507
Maker, A. V., Phan, G. Q., Attia, P., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Haworth, L. R., Levy, C., et al. (2005) · Annals of Surgical Oncology · doi:10.1245/aso.2005.03.536 · Cited by 492
Sarcoidosis is associated with a truncating splice site mutation in BTNL2
Valentonyte, R., Hampe, J., Huse, K., Rosenstiel, P., Albrecht, M., Stenzel, A., Nagy, M., Gaede, K. I., Franke, A., Haesler, R., et al. (2005) · Nature Genetics · doi:10.1038/ng1519 · Cited by 491
Current Perspective on the Pathogenesis of Graves’ Disease and Ophthalmopathy
Prabhakar, B. S., Bahn, R. S., & Smith, T. J. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0020 · Cited by 489
CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
Prieto, P. A., Yang, J. C., Sherry, R. M., Hughes, M. S., Kammula, U. S., White, D. E., Levy, C. L., Rosenberg, S. A., & Phan, G. Q. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1823 · Cited by 477
Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
Das, R., Verma, R., Sznol, M., Boddupalli, C. S., Gettinger, S. N., Kluger, H., Callahan, M., Wolchok, J. D., Halaban, R., Dhodapkar, M. V., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401686 · Cited by 461
PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
Goodman, A., Patel, S. P., & Kurzrock, R. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.168 · Cited by 461
Sage, P. T., Paterson, A. M., Lovitch, S. B., & Sharpe, A. H. (2014) · Immunity · doi:10.1016/j.immuni.2014.12.005 · Cited by 437
Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo
Read, S., Greenwald, R., Izcue, A., Robinson, N., Mandelbrot, D., Francisco, L., Sharpe, A. H., & Powrie, F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4376 · Cited by 434
CTLA-4 regulates induction of anergy in vivo
Greenwald, R. J., Boussiotis, V. A., Lorsbach, R. B., Abbas, A. K., & Sharpe, A. H. (2001) · Immunity · doi:10.1016/s1074-7613(01)00097-8 · Cited by 428
Ku, G. Y., Yuan, J., Page, D. B., Schroeder, S. E. A., Panageas, K. S., Carvajal, R. D., Chapman, P. B., Schwartz, G. K., Allison, J. P., & Wolchok, J. D. (2010) · Cancer · doi:10.1002/cncr.24951 · Cited by 422
CTLA-4-Mediated Inhibition of Early Events of T Cell Proliferation
Brunner, M. C., Chambers, C. A., Chan, F. K.-M., Hanke, J., Winoto, A., & Allison, J. P. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.10.5813 · Cited by 419
Co-stimulation in T cell responses
Chambers, C. A., & Allison, J. P. (1997) · Current Opinion in Immunology · doi:10.1016/s0952-7915(97)80087-8 · Cited by 415
Treg and CTLA-4: Two intertwining pathways to immune tolerance
Walker, L. S. K. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.06.006 · Cited by 411
Chambers, C. A., Sullivan, T. J., & Allison, J. P. (1997) · Immunity · doi:10.1016/s1074-7613(00)80406-9 · Cited by 411
Marron, M. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.8.1275 · Cited by 407
Recent advances in nanomaterial-based synergistic combination cancer immunotherapy
Sang, W., Zhang, Z., Dai, Y., & Chen, X. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00896e · Cited by 405
Bour‐Jordan, H., Esensten, J. H., Martinez‐Llordella, M., Penaranda, C., Stumpf, M., & Bluestone, J. A. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01011.x · Cited by 391
Self-citationT-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance
Ye, B., Liu, X., Li, X., Kong, H., Tian, L., & Chen, Y. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.42 · Cited by 391
Hurwitz, A. A., Yu, T. F.-Y., Leach, D. R., & Allison, J. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.10067 · Cited by 378
Costimulatory regulation of T cell function
Chambers, C. A., & Allison, J. P. (1999) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)80027-1 · Cited by 377
Distinct roles of CTLA‐4 and TGF‐β in CD4+CD25+ regulatory T cell function
Tang, Q., Boden, E. K., Henriksen, K. J., Bour‐Jordan, H., Bi, M., & Bluestone, J. A. (2004) · European Journal of Immunology · doi:10.1002/eji.200425143 · Cited by 377
Self-citationCTLA-4: a negative regulator of autoimmune disease.
Karandikar, N. J., Vanderlugt, C. L., Walunas, T. L., Miller, S. D., & Bluestone, J. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.2.783 · Cited by 376
Self-citationAt the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Intlekofer, A. M., & Thompson, C. B. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212621 · Cited by 371
CD28, CTLA‐4 and their ligands: who does what and to whom?
Sansom, D. M. (2000) · Immunology · doi:10.1046/j.1365-2567.2000.00121.x · Cited by 362
Chen, W., Jin, W., & Wahl, S. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.10.1849 · Cited by 352
Yuan, J., Gnjatic, S., Li, H., Powel, S., Gallardo, H. F., Ritter, E., Ku, G. Y., Jungbluth, A. A., Segal, N. H., Rasalan, T. S., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810114105 · Cited by 348
Maker, A. V., Attia, P., & Rosenberg, S. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.11.7746 · Cited by 343
The CD4‐related molecule, LAG‐3 (CD223), regulates the expansion of activated T cells
Workman, C. J., & Vignali, D. A. A. (2003) · European Journal of Immunology · doi:10.1002/eji.200323382 · Cited by 319
Sonkoly, E., Janson, P., Majuri, M.-L., Savinko, T., Fyhrquist, N., Eidsmo, L., Xu, N., Meisgen, F., Wei, T., Bradley, M., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.05.045 · Cited by 317
Mechanism of cellular rejection in transplantation
Ingulli, E. (2010) · Pediatric Nephrology · doi:10.1007/s00467-008-1020-x · Cited by 313
Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
Riera-Domingo, C., Audigé, A., Granja, S., Cheng, W.-C., Ho, P.-C., Baltazar, F., Stockmann, C., & Mazzone, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00018.2019 · Cited by 310
Schurich, A., Khanna, P., Lopes, R. A., Han, K. J., Peppa, D., Micco, L., Nebbia, G., Kennedy, P. T. F., Geretti, A.-M., Dusheiko, G., et al. (2011) · Hepatology · doi:10.1002/hep.24249 · Cited by 307
T cell anergy and costimulation
Appleman, L. J., & Boussiotis, V. A. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00009.x · Cited by 305
The role of CD28 and cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) in regulatory T‐cell biology
Sansom, D. M., & Walker, L. S. K. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00419.x · Cited by 293
Wang, S., Bajorath, J., Flies, D. B., Dong, H., Honjo, T., & Chen, L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021752 · Cited by 291
Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Regulates the Unfolding of Autoimmune Diabetes
Lühder, F., Höglund, P., Allison, J. P., Benoist, C., & Mathis, D. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.3.427 · Cited by 290
What's the difference between CD80 and CD86?
Sansom, D. M., Manzotti, C. N., & Zheng, Y. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00111-x · Cited by 289
CTLA4 gene polymorphism and autoimmunity
Gough, S. C. L., Walker, L. S. K., & Sansom, D. M. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00249.x · Cited by 288
Immunoregulatory control of Th1/Th2 cytokine profiles in periodontal disease
Gemmell, E., & Seymour, G. J. (2004) · Periodontology 2000 · doi:10.1111/j.0906-6713.2004.003557.x · Cited by 273
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Vafaei, S., Zekiy, A. O., Khanamir, R. A., Zaman, B. A., Ghayourvahdat, A., Azimizonuzi, H., & Zamani, M. (2022) · Cancer Cell International · doi:10.1186/s12935-021-02407-8 · Cited by 270
CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance
Friedline, R. H., Brown, D. S., Nguyen, H., Kornfeld, H., Lee, J., Zhang, Y., Appleby, M., Der, S. D., Kang, J., & Chambers, C. A. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081811 · Cited by 266
Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma
Maker, A. V., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Hughes, M., Yellin, M. J., Haworth, L. R., Levy, C., et al. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000208259.73167.58 · Cited by 265
Qian, J., Wang, C., Wang, B., Yang, J., Wang, Y., Luo, F., Xu, J., Zhao, C., Liu, R., & Chu, Y. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1330-2 · Cited by 260
Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS
Wang, S., Zhu, G., Chapoval, A. I., Dong, H., Tamada, K., Ni, J., & Chen, L. (2000) · Blood · doi:10.1182/blood.v96.8.2808 · Cited by 257
Immunotherapy in Melanoma: Recent Advances and Future Directions
Knight, A., Karapetyan, L., & Kirkwood, J. M. (2023) · Cancers · doi:10.3390/cancers15041106 · Cited by 256
A Native Soluble Form of CTLA-4
Oaks, M. K., Hallett, K. M., Penwell, R. T., Stauber, E. C., Warren, S. J., & Tector, A. J. (2000) · Cellular Immunology · doi:10.1006/cimm.2000.1649 · Cited by 256
Almerighi, C., Sinistro, A., Cavazza, A., Ciaprini, C., Rocchi, G., & Bergamini, A. (2009) · Cytokine · doi:10.1016/j.cyto.2008.12.009 · Cited by 221
Regulation of Cytotoxic T Lymphocyte-Associated Molecule-4 by Src Kinases
Chuang, E., Lee, K.-M., Robbins, M. D., Duerr, J. M., Alegre, M.-L., Hambor, J. E., Neveu, M. J., Bluestone, J. A., & Thompson, C. B. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.3.1270 · Cited by 119
Self-citationGastrointestinal toxicity of immune checkpoint inhibitors: From mechanisms to management
Samaan, M. A., Pavlidis, P., Papa, S., Powell, N., & Irving, P. M. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2018.14 · Cited by 100
Induction of Cytotoxic T Lymphocyte Antigen 4 (Ctla-4) Restricts Clonal Expansion of Helper T Cells
Doyle, A. M., Mullen, A. C., Villarino, A. V., Hutchins, A. S., High, F. A., Lee, H. W., Thompson, C. B., & Reiner, S. L. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.7.893 · Cited by 102
BUGEON, L., & DALLMAN, M. J. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.supplement_3.15tac5 · Cited by 94
CTLA-4 Ligation Suppresses CD28-induced NF-κB and AP-1 Activity in Mouse T Cell Blasts
Olsson, C., Riebeck, K., Dohlsten, M., & Michaëlsson, E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.20.14400 · Cited by 84
Wang, M., Liu, Y., Cheng, Y., Wei, Y., & Wei, X. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.12.002 · Cited by 66
Src Family Tyrosine Kinases Associate with and Phosphorylate CTLA-4 (CD152)
Miyatake, S., Nakaseko, C., Umemori, H., Yamamoto, T., & Saito, T. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9191 · Cited by 65
Mechanistic and pharmacologic insights on immune checkpoint inhibitors
Sweis, R. F., & Luke, J. J. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.012 · Cited by 37
Metadata
- Authors
- Walunas, T. L., Bakker, C. Y., & Bluestone, J. A.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1996-06-01
- Volume
- 183
- Issue
- 6
- Pages
- 2541-2550
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2164903177
- Cited by
- 801
- References
- 41
- FWCI
- 17.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.